Howard Jie Yang, William Spratt, Francis Yi Xing Lai, Senhong Lee
{"title":"Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature review.","authors":"Howard Jie Yang, William Spratt, Francis Yi Xing Lai, Senhong Lee","doi":"10.1080/09546634.2025.2495834","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>To evaluate the efficacy and adverse events of canakinumab in the treatment of pyoderma gangrenosum (PG).</p><p><strong>Methods: </strong>We report two cases of refractory PG treated with canakinumab after failing multiple therapies.</p><p><strong>Results: </strong>A 44-year-old female achieved complete ulcer resolution after 31 months of canakinumab but experienced recurrent infections, including pneumonia requiring intensive care unit (ICU) admission. A 49-year-old male showed no improvement and suffered recurrent <i>Pseudomonas</i> infections, leading to treatment cessation after nine months.</p><p><strong>Conclusions: </strong>We present a case series of two patients with PG on canakinumab therapy, both of whom experienced significant infections needing hospitalization. Further studies are needed to evaluate the efficacy and complication profile of canakinumab against other biologic therapy options.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2495834"},"PeriodicalIF":3.9000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of dermatological treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/09546634.2025.2495834","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/29 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: To evaluate the efficacy and adverse events of canakinumab in the treatment of pyoderma gangrenosum (PG).
Methods: We report two cases of refractory PG treated with canakinumab after failing multiple therapies.
Results: A 44-year-old female achieved complete ulcer resolution after 31 months of canakinumab but experienced recurrent infections, including pneumonia requiring intensive care unit (ICU) admission. A 49-year-old male showed no improvement and suffered recurrent Pseudomonas infections, leading to treatment cessation after nine months.
Conclusions: We present a case series of two patients with PG on canakinumab therapy, both of whom experienced significant infections needing hospitalization. Further studies are needed to evaluate the efficacy and complication profile of canakinumab against other biologic therapy options.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
